Wyeth OTC loratadine
This article was originally published in The Tan Sheet
Executive Summary
Company says it holds "first to file" ANDA status for orally disintegrating loratadine (Schering's Claritin Reditabs). Wyeth also has a pending 505(b)(2) application for OTC sale of the product. Firm recently told analysts Alavert launch would not be sidelined for six months by exclusivity issues (1"The Tan Sheet" Oct. 28, 2002, p. 4)...
You may also be interested in...
Andrx loratadine
Generics maker receives tentative FDA approval of ANDA (75-990) for orally disintegrating loratadine tablets (Schering's Claritin Reditabs) Nov. 15. Andrx previously was granted tentative approval for 24-hour loratadine/ pseudoephedrine combination (Claritin-D 24-Hour), for which it holds "first-to-file" status. Wyeth has said it holds FTF ANDA status for orally disintegrating loratadine (1"The Tan Sheet" Nov. 4, 2002, In Brief). FDA's target action date on Schering's switch NDAs for Claritin is Nov. 28; loratadine compound patent exclusivity expires Dec. 19...
Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.